Related Experiment Video
Updated: Sep 22, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antithrombotic agents in patients with COVID-19
Faizan Khan1, Tobias Tritschler2, Ryan Zarychanski2
1School of Epidemiology and Public Health (Khan), University of Ottawa; Clinical Epidemiology Program (Khan), Ottawa Hospital Research Institute, Ottawa, Ont.; Department of General Internal Medicine (Tritschler), Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; Department of Internal Medicine (Zarychanski), Max Rady Faculty of Health Sciences, University of Manitoba; CancerCare Manitoba (Zarychanski), Winnipeg, Man. fkhan039@uottawa.ca.
No abstract available in PubMed .
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Myocarditis III: Medical Management
Endocarditis III: Medical Management

